

## U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM</b>	<b>Application Number</b>	PCT/US2004/034944
	<b>Filing Date</b>	21 October 2004
	<b>First Named Inventor</b>	Christopher S. BROOK
	<b>Title</b>	2-(3,4-DIMETHYLPHENYL)-4-([2-HYDROXY-3'-(1H-TETRAZOL-5-YL)BIPHENYL-3-YL]-HYDRAZONO)-5-METHYL-2,4-DIHYDROPYRAZOL-3-ONE CHOLINE
	<b>Art Unit</b>	
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	PU60560

I hereby appoint:

☒ **Practitioners associated with the Customer Numbers. 20462**

Or

☐ Practitioner(s) named below:

Name	Registration Number

As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☐ The address associated with the above-mentioned Customer Number:

Or

☒ **The address associated with Customer Number 20462**

Or

☐ Firm or Individual Name:

Address:

Address:

City:

State:

Zip:

Country:

Telephone:

Fax:

I am the:

☐ Applicant/Inventor:☒ Assignee or record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**Signature: 

Date: 11 April 2006

Name: **Stephen Venetianer**

Telephone: 610-270-5040

Title and Company: **Vice President, Pharmaceuticals, SmithKline Beecham Corporation**

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.

Submit multiple forms if more than one signature is required, see below\*.

☐ \*Total of: \_\_\_\_\_ forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

A/D581-40

10/576411

AP20 REG. CTG. TO 20 APR 2006

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035


U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**STATEMENT UNDER 37 CFR 3.73(b)****Applicant/Patent Owner: SMITHKLINE BEECHAM CORPORATION****Application No./Patent No.: PCT/US2004/034944 Filed/Issue Date: 21 October 2004****Entitled: 2-(3,4-DIMETHYLPHENYL)-4-([2-HYDROXY-3'-(1H-TETRAZOL-5-YL)BIPHENYL-3-YL]-HYDRAZONO)-5-METHYL-2,4-DIHYDROPYRAZOL-3-ONE CHOLINE****SMITHKLINE BEECHAM CORPORATION, a corporation, states that it is:**

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ % in the patent application/patent identified above by virtue of either;
- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which copy thereof is attached.
- OR
- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:
1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
- ☐ Additional documents in the chain of title are listed on a supplemental sheet.
- ☒ Copies of assignments or other documents in the chain of title are attached.  
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

  
\_\_\_\_\_  
Signature11 April 2006  
\_\_\_\_\_  
DateSTEPHEN VENETIANER  
\_\_\_\_\_  
Printed or Typed Name610-270-5040  
\_\_\_\_\_  
Telephone NumberVice President, Pharmaceuticals  
\_\_\_\_\_  
Title

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT

WHEREAS we, CHRISTOPHER S. BROOK of 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States of America, a citizen of the United States of America, and LI-JEN J. PING of 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States of America, a citizen of United States of America, have made an invention entitled:

**2-(3,4-DIMETHYLPHENYL)-4-([2-HYDROXY-3'-(1H-TETRAZOL-5-YL)BIPHENYL-3-YL]  
HYDRAZONO)-5-METHYL-2,4-DIHYDROPYRAZOL-3-ONE CHOLINE**

for which on October 18 and 19, 2004 we executed an application for Letters Patent of the United States under 35 U.S.C. §111(a), executed an application for Letters Patents of the United States under 35 U.S.C. §371, or filed a Provisional application under 35 U.S.C. §111(b):

NOW, THEREFORE, in return for valuable consideration paid to us by SmithKline Beecham Corporation, a corporation organized under the laws of the Commonwealth of Pennsylvania and having its principal place of business at One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania 19103, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, we do hereby assign unto the said SmithKline Beecham Corporation, its successors and assigns, the entire right, title and interest in and to the said invention, executed under 35 U.S.C. §111(a), 35 U.S.C. §371, or filed under 35 U.S.C. §111(b) application, and from which priority may be claimed from one or more 35 U.S.C. §111(b) applications, or any division, continuation and continuation-in-part of said application, and all Letters Patent of the United States and all foreign countries to be obtained therefor;

We further assign to the said SmithKline Beecham Corporation the right, optionally in its own name or in the names of its related companies, to apply for, obtain and maintain in all countries foreign to the United States, patent and/or Utility Model applications for said invention, including the full right to claim for any such application the benefits of any priority rights based on said executed United States application;

And we agree to execute further instruments (including provisional, divisional, continuation, continuation-in-part or reissue applications or other instruments) proper to effectuate the premises, this agreement to be binding upon our heirs, executors and administrators;

And we request the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue Letters Patent in accordance herewith.

  
CHRISTOPHER S. BROOK

  
LI-JEN J. PING

Date: 19-Oct-2004

Date: 18-Oct-2004